Ensysce Biosciences 
ENSC was last quoted at $0.30, up 3.45% on the session (as of 10:29 AM ET, August 5), with a market capitalization of approximately $4.41 million against a float of roughly 9.27 million shares. The premarket reversal followed a session on August 4 in which the stock closed at $0.3842, up about 37%, on approximately 182 million shares traded. For context, Ensysce's average daily volume sits around 7 million shares, meaning August 4 volume ran roughly 26 times the norm.
The chart below shows ENSC's recent price action through August 5.
{
"chart_kind": "price_line",
"symbol": "ENSC",
"title": "ENSC daily closing price (June 24 - August 5, 2026)",
"timespan": "day",
"date_from": "2026-06-24",
"date_to": "2026-08-05",
"max_points": 30
}What Drove the August 4 Surge
The volume spike on August 4 did not come from a single headline announcement that day. Instead, momentum appears to have built on two overlapping catalysts flagged earlier in 2026.
First, Ensysce received a $5.3 million NIDA grant installment in July 2026, completing a multi-year $15 million federal award from the National Institute on Drug Abuse to support the PF614-MPAR overdose-protection program. The completion of that grant milestone had been circulating in investor channels leading into early August.
Second, the company has an ongoing strategic alternatives review that was initiated earlier in 2026. According to the company's profile and recent communications, this review is exploring potential partnerships, licensing deals, or asset sales tied to Ensysce's TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) platforms. Neither the timing nor the likely outcome of that process has been disclosed.
Clinical Progress Amid Thin Financials
On the clinical side, Ensysce enrolled its first patient in the final stage of the PF614-MPAR-102 study (the Phase I MPAR-102 cohort) after receiving IRB approval in April 2026. The company also expanded patent protection for its MPAR technology in May 2026, and CEO D. Lynn Kirkpatrick presented at the inaugural Clinical Pain Symposium in Amsterdam in May.
Those milestones are meaningful for a clinical-stage biotech, but the financial picture is thin. Ensysce entered Q1 2026 with approximately $745,000 in cash against total assets of $2.17 million and total liabilities of $2.84 million, leaving the company with negative equity of roughly $340,000. Free cash flow in Q1 2026 was negative $3.5 million. Ensysce had seven employees as of its most recent profile.
Valuation and Short Interest Context
ENSC is not profitable. The company reported Q1 2026 EPS of -$0.52 versus a consensus estimate of -$0.73, an earnings beat, though revenue of $1.0 million missed the $1.9 million estimate. Short interest fell 59.3% in March 2026, reducing but not eliminating short pressure.
The company's next scheduled earnings report is August 12, 2026, with consensus estimates of -$0.50 EPS and $1.9 million in revenue.
What the Premarket Reversal Signals
Premarket readings on August 5 indicated a 16-21% pullback from the prior close, suggesting that traders who rode the momentum spike on August 4 moved to lock in gains rather than hold through the uncertainty of an ongoing strategic review and thin cash position. The stock's intraday high near $0.48 on August 4 versus a current level near $0.30 underscores how far shares have compressed from that peak.
For investors considering ENSC at current levels, the tension is between speculative upside from a potential partnership or licensing deal and the operational reality of a seven-person company burning millions per quarter with less than $1 million in cash. The August 4 volume surge illustrates how a small-cap biotech with a high-news catalyst can attract outsized speculative flows, and the premarket reversal illustrates how quickly those moves can unwind.
Track ENSC's price, filings, and upcoming earnings with live data on Vantafin, and compare clinical-stage biotechs using the stock screener.